Phenotype of podoplanin-positive cells in the fibrotic tissue.
Maria Cimini
Antonio Cannatá
Gianandrea Pasquinelli
Marcello Rota
Polina Goichberg
10.1371/journal.pone.0173927.g003
https://plos.figshare.com/articles/figure/Phenotype_of_podoplanin-positive_cells_in_the_fibrotic_tissue_/4782253
<p>Thin cardiac sections were indirectly immunolabeled with antibodies that recognize podoplanin (red) and either fibronectin and vimentin (<b>A</b>; green and grey, respectively), VEGFR-2 and CD34 (<b>B</b> and <b>C</b>; green and grey, respectively), or α-SMA (<b>D</b>; grey). Nuclei, blue. Time after MI is indicated. Areas in rectangles are shown at higher magnifications in the adjacent images for each color channel. Note that vimentin (<b>A</b>) or α-SMA (<b>D</b>) labeling is rarely detectable in podoplanin-expressing cells (examples are pointed by yellow arrowheads). In <b>B</b> and <b>C</b>, the podoplanin-presenting cells show minimal VEGFR-2 labeling. At 2 days after MI, the podoplanin-bearing cells mostly do not co-stain with CD34 (exemplified by yellow arrowheads). Starting 2 weeks after MI, the CD34 staining is present in irregular capillary-like structures (examples are indicated by white arrows). In <b>C</b>, quantitative image analysis demonstrating changes in the podoplanin co-labeling with CD34 at indicated times after MI is included in the graph (lower panel). Data represent mean and SD of the co-localization coefficient; n = 5–6 image fields per group. By one-way ANOVA, *P < 0.02 for 2 weeks vs. 2 days; **P < 0.0001 for 1 month vs. 2 days; ns, not-significant for 1 month vs. 2 weeks.</p>
2017-03-23 18:02:48
lymphatic network
scar development
artery ligation
lymphatic vessel growth
sham-operated counterparts
lymphatic endothelium
Podoplanin-carrying populations
Podoplanin immunoreactivity
infarcted adult heart
infarcted myocardium
podoplanin-containing cells
infarcted heart
mesenchymal markers
infarcted hearts
infarcted region
scar formation
VEGFR -3
podoplanin-expressing cell populations
podoplanin-labeled cells
spatiotemporal changes
extracellular matrix deposits
LYVE -1-negative cells
fibrogenic responses
VEGFR -2 content
blood vessels
podoplanin-positive cell compartment
post-MI lymphangiogenesis
mouse model
wound granulation
infarcted myocardium Cardiac lymphatic vasculature
LYVE -1-positive lymphatic vessels
pro-fibrotic cells
master regulator
PDGFR
fibrotic area
hematoendothelial epitope CD 34.
podoplanin-presenting cells
podoplanin-rich LYVE -1-negative multicellular assemblies
Prox -1-positive